MTX1 and intrahepatic cholangiocarcinoma: These discoveries not only identify the NKILA‐MTX1/TOMM40 axis as a promising therapeutic target for ICC, but also lay a foundation for developing novel combination therapies that integrate metabolic modulation and immunotherapy to improve clinical outcomes.